chartexchange

INMB
INmune Bio Inc. Common stock
stockNASDAQ

At CloseNov 18, 2026 3:59:51 PM EST
1.02USD+6.250%(+0.06)765,457
Pre-marketNov 18, 2026 9:23:30 AM EST
0.986USD+2.708%(+0.026)
After-hoursNov 18, 2026 4:55:30 PM EST
1.11USD+8.824%(+0.09)
Loading…
Loading…
Healthcare
Biotechnology
HQ
Boca Raton, FL, USA
Previous Close
$0.96
Beta
2.54
52-Week High
$2.60 2026-09-08
52-Week Low
$0.89 2026-11-16
SMA 50
$1.70
SMA 200
$1.61
Avg. Vol 10D
463,535
Avg. Vol 30D
326,686
Avg. Vol 90D
359,781
Relative Vol
2.36
27.61M
1.1300%
4,300,000
474
INMB Profile

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient's immune system to treat cancer. inkmune, the company's lead product, primes patient's nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells' ability to eliminate residual disease.

INMB Performance
PeriodPriceDateChangeBeta
1W1.102026-11-11-7.73%4.434
1M1.542026-10-19-34.09%2.226
3M2.112026-08-18-51.90%2.216
6M1.492026-05-18-31.88%2.550
1Y1.502025-11-18-32.33%2.537
2Y4.872024-11-18-79.16%—
5Y13.712021-11-18-92.60%1.632
INMB Stock Summary

INmune Bio Inc. Common stock (NASDAQ:INMB) stock price today is $1.02, and today's volume is 770,693. INMB is up 5.729% today. The 30 day average volume is 326,686. INMB market cap is $31.42M with 30.96M shares outstanding.